Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated: SG&A Expense Trends

Gilead vs. Ligand: A Decade of SG&A Expense Trends

__timestampGilead Sciences, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014298300000022570000
Thursday, January 1, 2015342600000024378000
Friday, January 1, 2016339800000026621000
Sunday, January 1, 2017387800000028653000
Monday, January 1, 2018405600000037734000
Tuesday, January 1, 2019438100000041884000
Wednesday, January 1, 2020515100000064435000
Friday, January 1, 2021524600000057483000
Saturday, January 1, 2022567300000070062000
Sunday, January 1, 2023609000000052790000
Monday, January 1, 20246091000000
Loading chart...

Unleashing insights

SG&A Expense Trends: Gilead Sciences vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Gilead Sciences, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences experienced a significant increase of approximately 104% in SG&A expenses, reflecting its expansive growth and strategic investments. In contrast, Ligand Pharmaceuticals saw a more modest rise of around 134%, indicating a steady yet impactful growth strategy.

A Decade of Financial Insights

Gilead's SG&A expenses surged from $2.98 billion in 2014 to $6.09 billion in 2023, highlighting its aggressive market positioning. Meanwhile, Ligand's expenses grew from $22.57 million to $52.79 million, showcasing its focused approach in niche markets. These trends underscore the diverse strategies employed by these pharmaceutical giants in navigating the competitive landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025